Laird Norton Wetherby Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.14M | Sell |
5,470
-202
| -4% | -$84.4K | 0.09% | 212 |
|
|
2025
Q2 | $2.53M | Buy |
+5,672
| New | +$2.61M | 0.11% | 178 |
|
|
2024
Q4 | $2.25M | Sell |
5,582
-297
| -5% | -$138K | 0.11% | 184 |
|
|
2024
Q3 | $2.73M | Sell |
5,879
-84
| -1% | -$40.4K | 0.13% | 164 |
|
|
2024
Q2 | $2.79M | Buy |
5,963
+30
| +0.5% | +$13K | 0.13% | 148 |
|
|
2024
Q1 | $2.48M | Sell |
5,933
-13
| -0.2% | -$5.5K | 0.12% | 176 |
|
|
2023
Q4 | $2.42M | Buy |
5,946
+14
| +0.2% | +$5.17K | 0.13% | 166 |
|
|
2023
Q3 | $2.06M | Buy |
5,932
+107
| +2% | +$37.4K | 0.12% | 179 |
|
|
2023
Q2 | $2.05M | Sell |
5,825
-179
| -3% | -$60.3K | 0.11% | 183 |
|
|
2023
Q1 | $1.89M | Buy |
6,004
+213
| +4% | +$63.9K | 0.11% | 200 |
|
|
2022
Q4 | $1.67M | Buy |
5,791
+43
| +0.7% | +$13.1K | 0.11% | 206 |
|
|
2022
Q3 | $1.66M | Buy |
5,748
+540
| +10% | +$155K | 0.12% | 176 |
|
|
2022
Q2 | $1.47M | Sell |
5,208
-445
| -8% | -$119K | 0.1% | 208 |
|
|
2022
Q1 | $1.48M | Buy |
5,653
+425
| +8% | +$101K | 0.08% | 227 |
|
|
2021
Q4 | $1.15M | Buy |
5,228
+1,148
| +28% | +$223K | 0.06% | 286 |
|
|
2021
Q3 | $740K | Sell |
4,080
-327
| -7% | -$63.8K | 0.05% | 378 |
|
|
2021
Q2 | $889K | Sell |
4,407
-390
| -8% | -$81.6K | 0.05% | 336 |
|
|
2021
Q1 | $1.03M | Sell |
4,797
-290
| -6% | -$63.7K | 0.08% | 247 |
|
|
2020
Q4 | $1.2M | Sell |
5,087
-517
| -9% | -$119K | 0.08% | 231 |
|
|
2020
Q3 | $1.52M | Sell |
5,604
-116
| -2% | -$32K | 0.14% | 147 |
|
|
2020
Q2 | $1.66M | Buy |
5,720
+65
| +1% | +$17.6K | 0.16% | 124 |
|
|
2020
Q1 | $1.35M | Buy |
5,655
+449
| +9% | +$103K | 0.15% | 134 |
|
|
2019
Q4 | $1.14M | Buy |
5,206
+177
| +4% | +$35.8K | 0.11% | 196 |
|
|
2019
Q3 | $852K | Buy |
5,029
+260
| +5% | +$46K | 0.09% | 240 |
|
|
2019
Q2 | $874K | Buy |
4,769
+83
| +2% | +$14.5K | 0.1% | 230 |
|
|
2019
Q1 | $862K | Buy |
4,686
+137
| +3% | +$25.3K | 0.11% | 210 |
|
|
2018
Q4 | $754K | Buy |
4,549
+297
| +7% | +$51.5K | 0.11% | 215 |
|
|
2018
Q3 | $820K | Buy |
4,252
+225
| +6% | +$40.1K | 0.1% | 231 |
|
|
2018
Q2 | $684K | Sell |
4,027
-51
| -1% | -$7.91K | 0.09% | 263 |
|
|
2018
Q1 | $665K | Buy |
4,078
+375
| +10% | +$61.3K | 0.09% | 264 |
|
|
2017
Q4 | $555K | Buy |
3,703
+62
| +2% | +$9.18K | 0.08% | 322 |
|
|
2017
Q3 | $554K | Buy |
3,641
+263
| +8% | +$39.6K | 0.08% | 304 |
|
|
2017
Q2 | $435K | Buy |
3,378
+193
| +6% | +$23.2K | 0.07% | 332 |
|
|
2017
Q1 | $348K | Buy |
+3,185
| New | +$280K | 0.06% | 384 |
|
|
2016
Q4 | – | Sell |
-3,111
| Closed | -$271K | – | 547 |
|
|
2016
Q3 | $271K | Buy |
3,111
+669
| +27% | +$63.2K | 0.05% | 413 |
|
|
2016
Q2 | $210K | Sell |
2,442
-776
| -24% | -$67.1K | 0.05% | 452 |
|
|
2016
Q1 | $256K | Sell |
3,218
-306
| -9% | -$27.7K | 0.06% | 373 |
|
|
2015
Q4 | $443K | Sell |
3,524
-111
| -3% | -$13.4K | 0.11% | 227 |
|
|
2015
Q3 | $378K | Buy |
3,635
+785
| +28% | +$101K | 0.1% | 257 |
|
|
2015
Q2 | $352K | Buy |
2,850
+325
| +13% | +$41K | 0.08% | 273 |
|
|
2015
Q1 | $297K | Buy |
2,525
+157
| +7% | +$18.8K | 0.07% | 318 |
|
|
2014
Q4 | $282K | Buy |
2,368
+367
| +18% | +$41.3K | 0.07% | 322 |
|
|
2014
Q3 | $225K | Buy |
+2,001
| New | +$191K | 0.06% | 363 |
|
Other funds holding VRTX
Laird Norton Wetherby Wealth Management's VRTX Position: Q3 2025 in Review
Laird Norton Wetherby Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.6% in Q3 2025, selling an estimated $84.4K and leaving 5,470 shares worth $2.14M. The position accounts for 0.09% of the portfolio, ranked #212.
Laird Norton Wetherby Wealth Management first reported a position in VRTX in Q3 2014 and has held it in 43 quarters since. The position peaked at $2.79M in Q2 2024. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.
- Laird Norton Wetherby Wealth Management held 5,470 shares of Vertex Pharmaceuticals worth $2.14M as of Q3 2025.
- Laird Norton Wetherby Wealth Management sold 202 Vertex Pharmaceuticals shares in Q3 2025, an estimated $84.4K.
- Vertex Pharmaceuticals made up 0.09% of Laird Norton Wetherby Wealth Management's portfolio in Q3 2025, its #212 holding.
- Laird Norton Wetherby Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 43 quarters since.
- Laird Norton Wetherby Wealth Management's Vertex Pharmaceuticals position peaked at $2.79M in Q2 2024.
- 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.
Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.